Chris Mason, PhD

Dr. Mason is a Cofounder and Chief Science Officer at AvroBio, a clinical-stage, gene therapy company based in Cambridge, Massachusetts.

He also is a professor of cell and gene therapy in the Advanced Centre for Biochemical Engineering, University College London, working on the clinical translation and commercialization of cell and gene therapies. He has a multidisciplinary track record, spanning R&D, clinical practice, bioprocessing, regulation, healthcare economics, reimbursement and business.

He is on a number of national and international committees, working groups and initiatives related to the academic, clinical translation and commercialization of cell and gene therapies. He is the founder and CEO of the London Regenerative Medicine Network (LRMN) and a founding member of the UK-Israel Science Council. He also is on the Scientific Advisory Board of the UK Cell and Gene Therapy Catapult, Strategic Advisory Board of the Canadian Centre for the Commercialization of Regenerative Medicine (CCRM), and Scientific Advisory Board of the Canadian Stem Cell Network.

He is a general spokesperson for the cell and gene therapy sector, including frequent newspaper, radio and TV interviews.

He is Senior Editor of the journals Cell and Gene Therapy Insight and Regenerative Medicine.

He received his bachelor’s in molecular biology from Imperial College of Science, Technology and Medicine in 1993, an MBBS in medicine/surgery from United Medical and Dental Schools of Guy's and St. Thomas's Hospitals in 1994, and Ph.D. in biochemical engineering from University College London in 2005.